Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage

BMC Gastroenterology

Volumn 16, Issue 1, 2016, Pages

  Giamarellos Bourboulis, Evangelos J ^a   Pyleris, Emmanouel ^b   Barbatzas, Charalambos ^b   Pistiki, Aikaterini ^a   Pimentel, Mark ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Irritable bowel syndrome; Proton pump inhibitors; Small intestinal overgrowth

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BACTERIAL OVERGROWTH; BODY MASS; COHORT ANALYSIS; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; DUODENUM BIOPSY; GASTRITIS; GASTROINTESTINAL ENDOSCOPY; GOLD STANDARD; HUMAN; HUMAN TISSUE; IRRITABLE COLON; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PROSPECTIVE STUDY; PROTECTION; SMALL INTESTINE; BLIND LOOP SYNDROME; COMPLICATION; DUODENUM; MICROBIOLOGY; MIDDLE AGED;

AGED; BLIND LOOP SYNDROME; DUODENUM; HUMANS; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS;

EID: 84977618678     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/s12876-016-0484-6     Document Type: Article

References (16)

1. Lupascu A, Gabrielli M, Lauritano EC, Scarpellini E, Santoliquido A, Cammarota G, Flore R, Tondi P, Pola P, Gasbarrini G, Gasbarrini A. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22:1157-60.
2. Nucera G, Gabrielli M, Lupascu A, Lauritano EC, Santoliquido A, Cremonini F, Cammarota G, Tondi P, Pola P, Gasbarrini G, Gasbarrini A. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;2:1391-5.
3. Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci. 2010;55:2241-9.
4. Yu D, Cheeseman F, Vanner S. Combined oro-faecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-faecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011;60:334-40.
5. Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C, Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57:1321-9.
6. Choung RS, Ruff KC, Maljotra A, Herrick L, Locke 3rd GR, Harmsen WS, Zinsmeister AR, Talley NJ, Saito YA. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther. 2011;33:1059-67.
7. Camillieri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. 2012;367:1626-35.
8. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11:483-90.
9. Lee HR, Pimentel M. Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth. Curr Gastroenterol Rep. 2006;8:305.
10. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45 Suppl 2:1143-7.
11. Jacobs C, Coss Adame E, Attaluri A, Valsetin J, Rao SSC. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fundal overgrowth. Aliment Pharmacol Ther. 2013;37:1103-11.
12. Compare D, Pica L, Rocco A, De Giorgi F, Cuomo R, Sarnelli G, Romano M, Nardone G. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest. 2011;41:380-6.
13. Shah SC, Day LW, Somsouk M, Sewell JJ. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38:925-34.
14. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22-33.
15. Pistiki A, Galani I, Pyleris E, Barbatzas C, Pimentel M, Giamarellos-Bourboulis EJ. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. Int J Antimicrob Agents. 2014;43:236-41.
16. Jiang ZD, Ke S, Palazzini E, Riopel L, DuPont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother. 2000;44:2205-6.